SOURCE: Dynavax Technologies

Dynavax Technologies

September 16, 2010 09:30 ET

Dynavax to Present at the UBS Global Life Sciences Conference

BERKELEY, CA--(Marketwire - September 16, 2010) -  Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that its Chief Business Officer, Michael Ostrach, plans to make a formal presentation at UBS Global Life Sciences Conference 2010 on Monday, September 20, 2010 at 2:00 pm Eastern Time (11:00 am Pacific Time) at the Grand Hyatt Hotel in New York City, NY.

Mr. Ostrach will present a corporate overview, which will be webcast. To access the live webcast and the subsequent archived recording of the presentation, please log onto Dynavax's website at http://investors.dynavax.com/newsevents.cfm.

About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV™, an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

Contact Information

  • Contact:
    Michael Ostrach
    Vice President and Chief Business Officer
    510-665-7257
    Email Contact